Stakeholder survey about broad elements of value in health technology assessment in Australia: industry and academia more similar than different.

ABSTRACT:

Objective

Researchers propose wider individual and societal benefits (or broad elements of value) be included in economic evaluations (EEs) of medicines. This study investigates opinions of Australian stakeholders regarding the inclusion of broader value elements in reimbursement decisions for medicines for rare diseases in Australia.

Method

Stakeholders were invited via email to complete an online survey about their views on broader elements of value in HTA. Responses were summarised using descriptive statistics and compared using chi-square statistics.

Results

Forty-four respondents (academia (n=11), private sector (n=33)) completed the survey between October 2023 and May 2024. Only 27% of stakeholders agree the current information about the sources of value conside

SUBMITTER: Farris M 

PROVIDER: S-EPMC12390742 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature